2026 年 1 月 11 日（旧金山洲际酒店）——我们很欣喜地颁发，JDB电子将受邀在 雅法 ACCESS ASIA 药通亚洲 BD 论坛 @ JPM 2026 上颁发演讲 。
January 11, 2026 (InterContinental San Francisco) — We’re pleased to announce that Medicilon to speak at YAFO ACCESS ASIA BD Forum @ JPM 2026.
由雅法主办的ACCESS ASIA论坛，一连ACCESS CHINA的成功经验，将亚洲当先的生物科技跨境平台拓展至更辽阔领域，衔接创新者与全球药企、投资机构和战术合作同伴 。论坛将于2026年1月11日在旧金山洲际酒店进行，为亚洲生物科技企业提供全球舞台，展示创新成就，促成战术合作，启发贸易发展新机缘 。更多信息请接见：https://biotochina.org/
ACCESS ASIA, hosted by YAFO, builds on the success of ACCESS CHINA, expanding Asia’s leading cross-border biotech platform to connect innovators with global pharma, investors, and strategic partners.Taking place on January 11, 2026, at the InterContinental San Francisco, the forum provides a global stage for Asian biotech companies to showcase their innovation, foster partnerships, and explore new business development opportunities.
View more information at: https://biotochina.org/
演讲嘉宾
About the speaker
陈春麟博士 Dr. Chunlin Chen
首创人、董事长兼CEO Founder, Chairman and CEO
1986年毕业于中国药科大学,获药学硕士学位并于1994年毕业于美国俄克拉何马州立大学，获药理学及毒理学博士学位，中欧商学院EMBA 。毕业后从事多年药物的药理、毒理及生物化学钻研，在设计心血管药物、抗艾滋和抗癌新药的药代动力学和代谢方面有着很深的造诣 。2004岁首回国创办JDB电子 。公司已经为2000多家biotech、造药公司及大学和钻研所提供新药研发服务，并援手和支持超过580件创新药IND在中国、美国、澳大利亚、欧盟和韩国等获批进入临床钻研 。现担任中国药理学会药物代谢动力学专业委员会委员、上海欧美同学会生物医药分会会长及上海浦东生物医药协会副理事长等职务，同时还受聘为中国药科大学性命科学院客座教授 。幼我殊荣有：浦东新区“创业人才”奖(2005年)；上海市浦江人才(2007年)；上海市领武士才(2009年)；上海“归国创业精英奖(2009年)；国务院约请的北戴河休假专家(2009年)；上海市优良技术带头人(2011年)；上海张江高新技术产业开发区建设凸起贡献幼我(2011年)；获得商丘视装龙城英才打算”领武士才(2012年)；上海高科技园区“最周到药谷人奖” 。
Dr. Chen is Chairman, founder and CEO of Medicilon. Medicilon’s core business is to provide preclinical chemistry, ADMET and biology services to pharmaceutical companies and biotech companies. Prior to founding Medicilon, Dr. Chen had work experience in the USA, as a Staff Investigator at Department of Pharmacokinetics and Metabolism in Vertex Pharmaceuticals and as the Director of Pharmaceutical Department at Parker Hughes Cancer Center.In addition, Dr. Chen currently serves as Associate Director for Pharmacokinetics and Drug Metabolism Section of Shanghai Pharmacology Society and visiting Professor for China Pharmaceutical University. Dr. Chen got several awards including Excellent Teacher Award from China Pharmaceutical University, Research Excellent Award from Oklahoma State University. Medicilon has provided drug development services to over 2,000 clients worldwide and has assisted in the approval of 588 IND applications for clinical trials globally.
蔡金娜博士 Dr. Jinna Cai
首席商务官 Chief Business Officer
本科硕士博士均毕业于中国药科大学，博士期间曾在日本富山医科药科大学和汉药钻研所资源开发部参加合作钻研，随后在中科院上海药物所博士后流动站工作，有30多年中药新药和化学药产品开发钻研经验 。曾于1991年荣获国度中医药治理局科学技术进取一等奖，1992年荣获国度科学技术进取一等奖 。而后在汇仁集团研发部任钻研中心主任，荣获2004年汇仁公司“十佳”女员工和2006年被江西省经贸委评为“十五”全省企业技术中心治理先进幼我 。后于2008年7月参与JDB电子，先后任中国区市场启发总监、副总裁、商务发展部副总裁 。
Dr. Cai completed her whole high-level education at China Pharmaceutical University from Bachelor to Ph.D. Conducted research with Medical University of Toyama and Institution of Natural Medicine cooperatively. Later, she worked at Chinese Academy of Sciences Shanghai Institute of Materia Medica.
Over 30 years of dedication in new drug development and research. Was awarded the first Prize for Science and Technology Progress by the State Administration of Traditional Chinese Medicine in 1991 and National Awards for Science and Technology Grade I in 1992. Worked for Huiren Group as director of R&D Center for 5 years. Was awarded one of the top 10 employees by Huiren Group in 2006 and Excellent Management Individual of Provincial Technological Center during the “10th-five-year “by Jiangxi Province.
Dr. Cai joined Medicilon in July 2008 and took on the position of BD Head of Chinese market and then Vice President of BD Department.
林庆聪博士 Dr. Qingcong Lin
执行副总裁兼美国公司总裁 President at Medicilon USA Corp
美国纽约爱因斯坦医学院分子细胞生物学博士，曾陆续四年荣获“SAPA-NE服务奖”，获评“北京海表人才”、“漯河大学优良青老大师”等荣誉称号 。
林博士学术布景深厚，曾在美国阿尔伯特·爱因斯坦医学院Raju Kucherlapati’s 尝试室、哈佛大学医学院从事分子遗传学钻研等，曾任哈佛大学医学院遗传和基因组学钻研中心基因工程尝试室总监，在MCB、JBC等国际权威期刊上颁发24篇论文，并荣获多项发现专利 。多年学术浸润，使他在细胞生物学、分子生物学、免疫学、药理学、抗体药物发现和开发、发育生物学、生物信息学以及职能遗传学和基因组学等领域沉淀了极高的学术造诣和扎实的技术功底 。
深耕生物医药研发领域近40载，林博士不仅在学术界产生了沉要影响，也为全球生物医药行业的发展做出了卓越贡献，曾为跨国公司缔造子公司，组建多个科学团队，辅导百余个药物项目研发，在细胞生物学、分子遗传学、基因工程的肿瘤幼鼠模型钻研与利用领域颇有钻研，在抗体药物研发、杂交瘤细胞抗体和人噬菌体抗体库的成立、抗体基因工程、抗体人源化和亲和力提高与成熟，以及哺乳动物细胞抗体药物出产上, 堆集了丰硕的项目开发经验和治理智慧 。参与JDB电子之前，林博士曾担任惠氏造药资深科学家Ⅱ级、首席科学家Ⅰ级和Ⅱ级以及分子遗传学尝试室主任；辉瑞造药首席科学家Ⅱ级；盛诺基医药生物和抗体药物研发资深副总裁；百奥赛图资深副总裁兼Biocytogen Boston Corp（BBC）首席执行官等 。
Dr. Qingcong Lin holds a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine of Yeshiva University. He has conducted molecular genetics research in Raju Kucherlapati’s laboratory at Albert Einstein College of Medicine and Harvard Medical School. He has served as the Director of the Gene Modification Laboratory at Harvard-Partners Center for Genetics and Genomics (HPCGG). He has also published 24 papers in prestigious international journals such as MCB, JBC and holds multiple invention patents.
Having worked in the pharmaceutical R&D field for nearly 40 years, Dr. Lin has not only made significant impacts in academics but also contributed remarkably to the global pharmaceutical industry. Before joining Medicilon, Dr. Lin held positions such as Senior Scientist II, Principal Research Scientist I & II, and Director of Molecular Genetics Laboratory at Wyeth Research; Principal Research Scientist II and Group Leader at Pfizer Research; Senior VP of Biology and Antibody R&D at Shenogen Pharma Group; and SVP of Beijing Biocytogen, CEO of Biocytogen Boston Corp.
Dr. Lin has established subsidiary companies for multinational corporations, built multiple scientific teams, and has excellent drug R&D experience gained in more than 100 projects. Dr. Lin has accumulated rich experience in project development and management in antibody drug development, establishment of hybridoma cell antibodies and human phage antibody libraries, antibody gene engineering, antibody humanization, affinity maturation, and mammalian cell antibody drug production.
段茂圣博士 Dr. Maosheng Duan
药物发现事业部兼药学钻研事业部总裁 President of Drug Discovery and CMC Divisions
南开大学有机化学硕士，美国俄亥俄州立大学 （The Ohio State University）生物化学硕士，有机化学博士，国度级海表高档次专家；横跨国际大型药企、CRO和Biotech技术公司，在生物医药领域耕作25年，堆集了研发、运营和治理的丰硕经验 。
段博士亲自主持了从立项、PCC、IND钻研和申报、直至临床钻研的全链条药物研发 。不仅理解药物开发流程，并且宽泛涉猎药物化学、CMC、生物学、药理学、药代动力学、毒理学等多个领域，把握各类数据解读，推进高效决策 。此表，作为主题治理者，段博士善于辅导跨部门、跨学科团队合作，有效整合多方资源，推动研发管线，在抗病毒、抗肿瘤、代谢性疾病、免疫学等疾病领域别离将多个分子推动到 IND和临床钻研的分歧阶段，并有两款药物获得FDA核准上市 。段博士跟紧生物医药技术前沿，对共价抑造剂，ADC，PROTAC、幼核酸等领域有着深刻的见解 。段博士占有34项发现专利，并在权威学术期刊上颁发了28篇经过同业评审的高质量学术论文 。
参与JDB电子之前，段博士曾任GSK首席科学家，堆集了10年幼分子药物研发经验；在辉源生物担任副总裁期间，实现从0-1构建药物化学服务部，为国内表药企提供了强有力的药物研发支持直大公司被药明康德收购 。因而，深谙CRO“质量-效能-交付”的服务宗旨；作为越之康泰生物的共同首创人、首席执行官及首席科学官，辅导公司运营、研发及临床开发，成功推动了公司资产在2020年被收购；在纳肽得生物担任首席执行官期间，主导幼核酸(siRNA)技术平台建设和项目管线开发，并通过商务BD，成功实现了管线对表授权（license out）和买卖 。这些丰硕经历和卓越成就，将为JDB电子的发展注入强劲动力 。
Dr. Maosheng Duan holds a Master’s degree in Organic Chemistry from Nankai University in Tianjin, China, as well as a Ph.D. in Organic Chemistry and a Master’s degree in Biochemistry from The Ohio State University in the USA. With over 25 years of experience in the pharmaceutical and biotech industry, Dr. Duan has worked across international big pharma, CROs, and biotech companies, gaining extensive expertise in R&D, operations, and management. Prior to joining Medicilon, Dr. Duan held key leadership roles at prominent organizations, including GSK, HD Biosciences, YueZhi KangTai Biomedicine, and NanoPeptide Biotechnology.
Dr. Duan has directed and led the entire drug research and development process, from project initiation and PCC nomination to IND enabling, filing, and clinical studies. He possesses not only a broad understanding of the drug R&D process but also deep expertise in medicinal chemistry, CMC, biology, pharmacology, pharmacokinetics, toxicology, and clinical regulations. Additionally, Dr. Duan is highly skilled in interpreting diverse types of data to facilitate efficient decision-making.
As a core leader, Dr. Duan excels in guiding cross-functional and interdisciplinary teams, effectively integrating resources to advance R&D pipelines. He has successfully progressed multiple molecules through various stages, from IND filings to clinical studies and NDAs, in the fields of antiviral, antitumor, metabolic diseases, and immunology, with two FDA-approved drugs. Dr. Duan remains at the forefront of biomedical technologies, offering unique insights into cutting-edge areas such as covalent inhibitors, ADCs, PROTACs, and RNAi. His accomplishments include 34 invention patents and 28 publications in peer-reviewed journals.
关于ACCESS ASIA药通亚洲 BD Forum @ JPM 2026
2026 年 1 月 11 日， ACCESS ASIA 药通亚洲BD论坛 @ JPM 2026 将在美国旧金山洲际酒店正式进行 。
ACCESS ASIA BD Forum @ JPM is scheduled to be held on January 11, 2026, at the InterContinental San Francisco, alongside the J.P. Morgan Healthcare Conference Week.
本次为期一天的论坛将出现主题演讲、圆桌会商、企业路演、公司展示，以及 1 对 1 合作洽谈，旨在衔接亚洲当先的生物科技创新者与全球造药公司、投资机构及战术合作同伴 。
This full-day forum will feature keynote speeches, panel discussions, corporate presentations, company showcases, and 1-on-1 partnering meetings connecting Asia’s leading biotech innovators with global pharma, investors, and strategic partners.
会议名称:ACCESS ASIA 药通亚洲BD论坛 @ JPM 2026
功夫 & 地址: 2026 年 1 月 11 日 | 旧金山洲际酒店
更多活动详情请至: https://biotochina.org/
扫描二维码注册
